E. Coli Nissle 1917 - Suspension for Infection Prophylaxis

PHASE3CompletedINTERVENTIONAL
Enrollment

567

Participants

Timeline

Start Date

October 7, 2015

Primary Completion Date

October 12, 2020

Study Completion Date

October 12, 2020

Conditions
Infections
Interventions
DRUG

EcN-Suspension

"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day)."

DRUG

Placebo

"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day)."

Trial Locations (6)

14467

Klinikum Westbrandenburg, Potsdam

18059

Klinikum Südstadt Rostock - Abteilung für Neonatologie, Rostock

06110

Krankenhaus St. Elisabeth & St. Barbara, Halle

07747

Universitätsklinikum Jena - Klinik für Kinder- und Jugendmedizin, Jena

85-168

"Oddział Kliniczny Noworodków, Wcześniaków z Intensywną Terapią Noworodka wraz z Wyjazdowym Zespołem N", Bydgoszcz

02-091

Samodzielny Publiczny Dziecięcy Szpital Kliniczny Oddział Kliniczny Neonatologiiul, Warsaw

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ICON plc

INDUSTRY

collaborator

Clinscience Sp. z o.o.

UNKNOWN

lead

Ardeypharm GmbH

INDUSTRY

NCT02802059 - E. Coli Nissle 1917 - Suspension for Infection Prophylaxis | Biotech Hunter | Biotech Hunter